Mednet Launches New Healthcare Software
New module designed to provide simple storage of participant consent.
Mednet announced in a company press release its newest software release. Featuring electronic consent capabilities (eConsent) within the iMednet eClinical platform, the organization stated that the new module was designed to provide a simple, cost-effective, and compliant method to collect and store participant consent.
"As the use of electronic consent in clinical trials becomes increasingly necessary across all study types – we are thrilled to add this to our comprehensive toolset," said Rob Robertson, CEO, Mednet, in a company press release. "I am particularly proud of how our team diligently listened to our customers and translated their needs to deliver the optimal combination of functionality, flexibility, and affordability."
Reference: Mednet Launches eConsent Functionality in Latest Release. PR Newswire. October 4, 2023. Accessed October 6, 2023. https://www.prnewswire.com/news-releases/mednet-launches-econsent-functionality-in-latest-release-301947495.html
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
